Despite the improvement in the quality of life of patients with SLE due to scientific and technological advances, SLE remains a disease that over the years may produce irreversible damage to patients. Osteoporosis and secondary bone fractures are two of the major causes of irreparable injury in patients with SLE. Vitamin D insufficiency may play a vital role both in reduced Bone Mineral Density (BMD) and in the appearance of fractures, although its mechanisms of action are still unclear. We performed a systematic review of the literature in order to determine the prevalence and predictors of reduced vitamin D plasma levels, bone loss and the presence of fractures in SLE patients. Our review encompassed all English-language publications using Medline and EMBase electronic databases from their inception (1966 and 1980, respectively) to December 2016. We included all intervention studies and observational studies in which vitamin D plasma levels, BMD and bone loss were measured and applied to patients with SLE. Previous studies suggested an increase in bone loss and fracture in patients with SLE compared with general population and although there is a high prevalence of vitamin D insufficiency in the general population, previous studies had demonstrated lower vitamin D levels in patients with SLE compared to agematched controls. The etiology of reduced bone mass and reduced vitamin D plasma levels in SLE is multifactorial and includes a variety of intrinsic factors related to the disease itself and treatment side effects. SLE patients are at risk for developing these two comorbidities (reduced vitamin D plasma levels and low BMD) and it is therefore essential to study, monitor, prevent and treat bone metabolism disorders in SLE patients.
A C C E P T E D M A N U S C R I P T
Osteoporosis is a condition of decreased bone mass density that increases the bone fracture risk. The continual resorption and re-deposition of bone mineral, or bone remodeling, are intimately tied to the pathophysiology of osteoporosis. Previous studies have suggested an increase in bone loss and fracture in patients with SLE compared with general population (7). Moreover, although there is a high prevalence of vitamin D insufficiency in the general population, previous studies have demonstrated lower vitamin D level in patients with SLE than age-matched controls (8,9). The origin of these two conditions is multifactorial and the objective of this systematic literature
review is to describe the prevalence and predictors of these two comorbidities vis-à-vis the natural history of this disease.
Methodology
We conducted a systematic review of all English language publications using Medline 
Bone loss in SLE
Previous studies have suggested possible bone loss and fracture risk in patients with SLE (3,10). Reduced bone mass in SLE male (11) and female (12) patients has been
shown to be more prevalent compared to age-matched healthy controls. Osteoporosis is defined as a systemic skeletal disease characterized by decreased bone mineral density (BMD) (13) and an increase in the susceptibility to bone fractures. Traditionally, osteoporotic fractures are localized in several specific skeletal sites: hip, wrist and spine. There is recent evidence that autoimmunity and associated inflammation and even vitamin D deficiency play key roles in the pathogenesis of negative skeletal effects in SLE patients (2) . Several factors such as physical inactivity, persistent
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A C C E P T E D M A N U S C R I P T inflammation, and corticosteroids treatment may contribute to the presence of decreased bone mass in SLE. Osteopenia in the lumbar spine and or the hip has been reported in 25-74% of patients with SLE, and osteoporosis in 1.4-68% of patients with SLE in cohort studies (14) . This wide variation might be due to differences in body mass index (BMI), age, sex, ethnic background, disease severity, medication use and study design. 
A C C E P T E D M A N U S C R I P T hip and femoral neck in this patient cohort (2) . These findings demonstrate the necessity of evaluating BMD not only at the spine but also at the femoral neck and hip in patients with SLE.
As mentioned, the exact degree to which inflammatory activity per se, versus vitamin D plasma levels and BMD, contributes to fractures remains as an open question. An interesting and recently published study involving markers of bone turnover assessed bone metabolism in 60 male Chinese patients recently diagnosed with SLE. Here, osteocalcin (bone formation marker) was negatively associated with SLE disease activity, while β-crosslaps (bone resorption marker) was positively associated with SLE disease activity. This suggests that SLE disease activity itself directly contributed to the development of SLE-associated low BMD (21).
In regards to corticosteroids treatment, although its effect on RANK-L (22) is well known, the true incidence of low BMD in SLE patients taking corticosteroids remains an open question. In the Dutch cohort of SLE patients published in 2013 (15) , in which BMD and the factors that could influence it were followed for up to 6 years, an association was found between reduced BMD and corticosteroids use. For all these reasons, and despite several studies that found no such association (16), we believe there is sufficient evidence to recommend vigilance in detecting and preventing osteoporosis in patients with SLE and extended use of corticosteroids. In fact, apart from the direct action on bone tissue by corticosteroids, the presence of low vitamin D levels may generate a secondary hyperparathyroidism, which is another mechanism that accentuates bone resorption.
To date, many retrospective and transversal studies have examined the predictive factors of bone loss in SLE. In contrast, there have been few longitudinal studies (15, ACCEPTED MANUSCRIPT These observations are particularly important for patients with SLE since the causes of increased bone fragility in patients with SLE remain unclear.
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In conclusion, this systematic review provides strong evidence on the relationship between SLE and bone loss and fracture risk. Not only do SLE patients have significantly lower BMD than controls, but SLE is also associated with increased fracture risk. Clinicians should be aware of these findings, which underscore the importance of preventing bone loss and the need for detecting and treating osteopenia and osteoporosis in patients with SLE. Nonetheless, many questions remain open and further studies are needed to clarify these questions. Why vitamin D plasma levels in lupus patients do not increase despite good dietary or pharmacological supplementation might be due to possible malabsorption of vitamin D supplements by an SLE-specific gastrointestinal problem. To date, however, the only things documented are that the malabsorption in SLE, which has a prevalence of 9.5%, is sometimes associated with celiac disease, and that patients with the latter have a 3X
Vitamin D and systemic lupus erythematosus
higher risk of developing SLE compared to general population (65, 66) . 
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Conclusions
The expression of these two situations (reduced vitamin D plasma levels and low BMD), illustrates how preventable comorbidities can increase SLE disease activity, resulting in accumulated damage, worse prognoses, and the need for other therapies
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in SLE patients. In these patients, musculoskeletal problems are the most prevalent symptom while pain levels can become increasingly incapacitating when an osteoporotic fracture occurs. As previously stated, choosing an appropriate design for evaluate these variables (BMD, bone loss and vitamin D plasma levels) is imperative in SLE patients, not only to avoid confounding factors, but also to permit accurate defining of the real predictors affect such aforementioned variables. It has been postulated that good control of disease activity and monitoring of BMD and vitamin D plasma levels are useful tools for improving bone quality in these patients. In conclusion, as SLE patients are at risk for developing these two comorbidities (reduced vitamin D plasma levels and low BMD), it is essential to properly study, monitor, prevent and treat disorders of bone metabolism in SLE patients.
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